RE:We Sit and WaitI dont know where you're getting your information but thats not my take on it.
BTD moves the needle for SP, AA moves the needle for treatment and revenue streams
BTD has a 1 in 5 approval rate.
BTD is on track for Q1 submittal. The data being collected from the remaining candidates reinforces our long term CR numbers, which is the differentiator between the other competeting drugs and justification for the designation. Otherwise our shorter term CR numbers, while good, are comparable to alternatives. It needs to be done properly for the best chance of approval.
We have the patient data needed for AA, we just need to complete patient enrollment. We do not have direct control over enrollment but I believe we are about 12-25 patients away. The requirements are different for the FDA and the same approval in Canada as far as I uderstand.
AA will be a game changer for whatever direction the company goes in to get to market.
Its getting done. Lets do it right. Im buying more.